9+ weeks
Panorama® is a safe and simple way for expectant mothers to gain certain information about the health of their fetus without an invasive diagnostic procedure. Panorama uses a simple blood draw from the mother to examine cell-free DNA found in maternal blood originating from both mother and fetus to screen for chromosome abnormalities, including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), monosomy X (Turner syndrome), and triploidy. The screening test can be performed as early as nine weeks of gestation and there is no risk to the fetus.
Natera® is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system.
Tests include the Spectrum® pre-implantation genetic test for embryo selection during IVF; the Anora® miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama® non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer.

Click here to visit: Panorama test for Patients
TEST | NATERA |
---|---|
Company website | http://global.panoramatest.com/uk |
COMPANY | Natera |
Test Origin | USA |
Laboratory Location | USA (Currently) |
Type of cfDNA analysis | SNP-Based Next-Generation Sequencing |
Screen Population | General, Low and High risk |
Number of tests performed | >475,000 (as of December 2015) |
Clinical data number re test performance | >20,000 |
About the test | |
Gestational age | 9+ weeks |
Pregnancies Screened | |
Singletons | |
Naturally conceived | YES |
IVF (Self) | YES |
IVF (Donor) | No |
Multiples (Twins) | |
Naturally conceived | No |
IVF (Self) | No |
IVF (Donor) | No |
Risk analysis | All give individualized risk score plus high / low result for each patient |
Fetal fraction redraw level | 2.8% Minimum |
Fetal fraction quoted | Yes |
Redraw rate | 4% (~3% average for UK) |
Chance of result after 2nd blood sample | 68% |
Chromosomes analysis | Current validated detection rates (08/14) |
Combined false positive rate T12/T18/T13 | <0.1% |
T21 Down’s syndrome | >99% |
T18 Edwards’ syndrome | >96.4% |
T13 Patau’s syndrome | >99% |
Triploidy | YES |
Fetal sex / presence of Y chromosome: accuracy | YES: 100% |
Sex Aneuploid Conditions | YES |
X0 (Turner syndrome) | YES |
XXX (Triple X) | YES |
XYY (Jacob’s syndrome) | YES |
XXY (Klinefelter syndrome) | YES |
Micro deletions (Optional) | YES: 22q, Cri-du-Chat, 1p36, Angelman, Prader-Willi |
Turnaround Time (TAT) working days | UK average: 4 business days from receipt of sample |